Wexner Medical Center performs first gene therapy brain infusion for Parkinson’s disease
For the first time ever, a team of neurologists and neurosurgeons at The Ohio State University Wexner Medical Center and The Ohio State College of Medicine has performed a novel gene therapy brain infusion to treat a patient with Parkinson’s disease.
This multicenter, Phase 1b clinical safety study is sponsored by Brain Neurotherapy Bio, Inc. and funded by the California Institute for Regenerative Medicine to test GDNF gene therapy in patients with early to moderate stages of Parkinson’s disease. The one-time treatment involves infusion of a gene therapy solution into deep structures of the brain that are affected by the disease.
